Abstract
Background This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death.
Methods An observational longitudinal study was conducted during the first year of pandemic SARS-CoV-2 (1st March 2020 to 1st March 2021). All pediatric patients attended at the rheumatology outpatient clinic of six tertiary hospital in Madrid, Spain, with a medical diagnosis of RMD and COVID-19 were included. Main outcomes were symptomatic disease and hospital admission. The covariates were sociodemographic, clinical, and treatments. We ran a multivariable logistic regression model to assess risk factors for outcomes.
Results The study population included 77 pediatric patients. Mean age was 11.88 (4.04) years Of these, 30 patients were asymptomatic, 41 had a mild or moderate disease and other 6 patients (7.79%) required hospital admission related to COVID-19. The median length of stay was 5 (2–20) days and there was no death. Previous comorbidities increased the risk for symptomatic disease and hospital admission. Compared with outpatients, the factor independently associated with hospital admission was the use of glucocorticoids (OR 1.08; p=0.00). No statistically significant findings for symptomatic COVID-19 were found in the final model.
Conclusion Our data found no differences in COVID-19 outcomes between children-onset rheumatic diseases. Our results suggest that associated comorbidities and being in treatment with glucocorticoids increase the risk of hospital admission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Hospital Ramon y Cajal Institutional Ethics Committee (approval number 136-20).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* AB and LA shared senior authorship
Abbreviations
- ACE
- angiotensin-converting-enzyme inhibitors
- CAPS
- cryopyrin-associated periodic syndrome
- COVID-19
- Coronavirus disease 2019
- DMARD
- disease-modifying anti-rheumatic drug cs
- DMARDs
- classic DMARDs
- ts/bDMARDs
- targeted synthetic or biologic DMARDs
- FMF
- familial Mediterranean fever
- JAK
- Janus-Kinasa
- JIA
- juvenile idiopathic arthritis
- HIDS
- hyperimmunoglobulin-D syndrome
- IQR
- interquartile Range
- MIS-C
- multisystem inflammatory syndrome in children
- MKD
- mevalonate kinase deficiency
- NSAID
- nonsteroidal anti-inflammatory drugs
- PCR
- polymerase chain reaction
- PFAPA
- periodic fever, adenopathy, pharyngitis and aphthous stomatitis
- RMD
- rheumatic and musculoskeletal diseases
- SARS
- severe acute respiratory syndrome
- TNF
- tumor necrosis factor
- TRAPS
- TNF- receptor associated periodic syndrome
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos